| Oct 28 |
Vera Therapeutics announces proposed public offering of class A common stock
|
| Oct 28 |
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
|
| Oct 28 |
Vera stock closes 15% higher in wake of positive atacicept data
|
| Oct 28 |
Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years
|
| Oct 28 |
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
|
| Oct 28 |
Vera Therapeutics Eyes Breakout On Promising Results For Kidney Drug
|
| Oct 26 |
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
|
| Oct 4 |
Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients
|
| Oct 2 |
Vera to expand atacicept program into broader IgAN population
|
| Oct 2 |
Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024
|
